TYSABRI is a prescription medication approved for patients with relapsing forms of multiple sclerosis (MS), and is now indicated for appropriate patients with Crohn's disease.

TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies.

TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.

In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α.